CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
NH002 (Perflutren Lipid Microspheres) Injectable Suspension +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04185246
NCT04185246Phase 2Completed
CompareCT.gov

A Multicenter, Open-Label, Dose Ascending Study to Evaluate the Safety of NH002 as a Contrast Agent in Cardiac Echocardiography

Trust Bio-sonics, Inc.·interventional·Posted Dec 4, 2019·Updated Nov 18, 2025

In Brief

A Phase 2 clinical trial evaluating NH002 (Perflutren Lipid Microspheres) Injectable Suspension and Echocardiogram for Cardiac Disease. Completed, enrolled 36 participants across 2 sites.

Detailed Summary

NH002 (Perflutren Lipid Microspheres) Injectable Suspension is an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular (LV) chamber and to improve the delineation of the LV endocardial border. The primary objective of this study is to evaluate the safety and tolerability of 3 ascending doses of NH002.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiac Disease
CountriesTaiwan
CollaboratorsStatPlus,Inc.

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedDec 4, 2019
Enrollment StartNov 4, 2019
Primary CompletionJul 1, 2020
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 6.6 years ago

Interventions

NH002 (Perflutren Lipid Microspheres) Injectable Suspensiondrug

NH002 is formulated as a microbubble injectable suspension for intravenous administration. NH002 requires an activation process prior to use.

Echocardiogramother

Each patient will undergo an unenhanced ultrasound examination and a NH002 contrast-enhanced examination on the same day.